Press release
SIGA Reports Financial Results for Three Months Ended March 31, 2025
Received $26 Million IV TPOXX Procurement Order from the U.S. Government in March$94 million in TPOXX Orders (to be Delivered to U.S. Strategic National
About this update from Siga Technologies Inc.
[{"type":"text","content":"Received $26 Million IV TPOXX Procurement Order from the U.S. Government in March$94 million in TPOXX Orders (to be Delivered to U.S. Strategic National Stockpile) outstanding as of March 31, 2025Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2025. “SIGA has carried its momentum from 2024 into 2025, achieving steady progress on its key initiatives,” stated Diem Nguyen, Chief Executive Officer. “In the first quarter, an international sale of approximately $6 million marks what we expect to be the beginning of substantial sales over the next series of months. With outstanding Strategic National Stockpile orders of $94 million as of March 31, 2025, we expect to deliver the $70 million of orders outstanding as of December 31, 2024 by the end of the third quarter of 2025, with the remainder expected to be delivered in 2026. We view these anticipated sales as a strong base upon which to build.” Summary Financial Results ($ in millions, except per share amounts) Three Months Ended March 31 2025 2024 Product sales (1) $5.8 $23.9 Total revenues (2) $7.0 $25.4 Operating (loss) / income(3) $(2.3) $11.3 (Loss) / Income before income taxes $(0.6) $13.2 Net (loss) / income $(0.4) $10.3 Diluted (loss) / income per share $(0.01) $ 0.14 (1) Includes supportive services related to product sales.(2) Includes research and development revenues.(3) Operating (loss)/income excludes, and (loss)/income before income taxes includes other income. Both line items exclude the impact of income taxes. Key Business and Operational Activity: In April 2025, the Company delivered approximately $53 million of oral TPOXX and approximately $9 million of IV TPOXX to the SNS.In April 2025, the Company’s 19C contract with the U.S. Government was modified to add $14 million of funding for activities to support manufacturing.In March 2025, the Company received a procurement order for $26 million of IV TPOXX from the U.S. Government under the 19C BARDA contract.In March 2025, the Company delivered approximately $6 million to an international customer, representing a sale to this country in five out of the last six years.In January 2025, the Company announced that TPO...